ORC-13661

Developed for: drug-induced hearing loss
Investigated by: Johns Hopkins University · Kevin Winthrop · Mayo Clinic · Medical University of South Carolina · National Center for Advancing Translational Sciences (NCATS) · National Institute on Deafness and Other Communication Disorders (NIDCD)
+6 more
· National Jewish Health · Northwell Health · Oricula Therapeutics · The University of Texas Health Science Center at Tyler · University of California, San Francisco · University of Washington

today NCT05730283 · Ph 2

202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05730283	Jun 2025 → Feb 2028 expected	drug-induced hearing loss	Kevin Winthrop	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	ORC-13661	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05730283 ↗
Modality	Small molecule	“ORC-13661, a small molecule compound being developed as an adjunct therapy” NCT05730283 ↗